Health & Medicine
Legend Biotech stock surges on strong Q1 CAR T-cell therapy results
Legend Biotech's stock recently jumped 42% following new data, propelled by early clinical successes in difficult-to-treat cancers and robust sales of its existing CAR-T therapy, CARVYKTI, according t
Aram Sarkisian·June 4, 2026